IART icon

Integra LifeSciences

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 75%
Negative

Neutral
GlobeNewsWire
5 days ago
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & Medicaid Services (CMS) on its Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules.
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
Neutral
GlobeNewsWire
19 days ago
Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its CUSA® Clarity Ultrasonic Surgical Aspirator System for cardiac surgeries.
Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries
Neutral
Seeking Alpha
1 month ago
Integra LifeSciences Holdings Corporation (IART) Q3 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation ( IART ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christopher Ward - Senior Director of Investor Relations Mojdeh Poul - President, CEO & Director Lea Knight - Executive VP & CFO Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Presentation Operator Good day, and welcome to the Integra LifeSciences Third Quarter 2025 Financial Results. [Operator Instructions] As a reminder, this call may be recorded.
Integra LifeSciences Holdings Corporation (IART) Q3 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
1 month ago
Integra (IART) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra (IART) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Positive
Zacks Investment Research
1 month ago
Integra LifeSciences (IART) Q3 Earnings Beat Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.41 per share a year ago.
Integra LifeSciences (IART) Q3 Earnings Beat Estimates
Neutral
GlobeNewsWire
1 month ago
Integra LifeSciences Reports Third Quarter 2025 Financial Results
PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025.
Integra LifeSciences Reports Third Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 month ago
Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025
PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to the market open.
Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025
Neutral
GlobeNewsWire
1 month ago
Integra LifeSciences to Spotlight Neurosurgical Product Portfolio at the Congress of Neurological Surgeons (CNS) Annual Meeting
Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post
Integra LifeSciences to Spotlight Neurosurgical Product Portfolio at the Congress of Neurological Surgeons (CNS) Annual Meeting
Neutral
GlobeNewsWire
2 months ago
Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer.
Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer
Negative
Zacks Investment Research
2 months ago
Should You Continue to Hold Integra Stock in Your Portfolio Now?
IART shows strong demand in neurosurgery and Tissue Technologies but faces macro and liquidity challenges.
Should You Continue to Hold Integra Stock in Your Portfolio Now?